British Fertility Society Policy and Practice Committee: Prevention of Ovarian Hyperstimulation Syndrome

References

• Abdalla, H.I., Ah-Moye, M., Brinsden, P., Howe, D.L., Okonofua, F., & Craft, I. (1987). The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fertility and Sterility, 48, 958–963.
   PubMed Web of Science ®Google Scholar
• Abdalla, S. & Nicopoullos, J. (2010). The effect of duration of coasting and estradiol drop on the outcome of assisted reproduction: 13 years of experience in 1,068 coasted cycles to prevent ovarian Hyperstimulation. Fertility and Sterility, 94, 1757–1763.
   Google Scholar
• Al-Inany, H.G., Youssef, M.A., Aboulghar, M., Broekmans, F.J., Sterrenburg, M.D., Smit, J.G., & Abou-Setta, A.M. (2011). Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews, 5, Art. No.: CD001750. doi:10.1002/14651858.CD001750.pub3.
   Google Scholar
• Alvarez, C., Marti-Bonmati, L., Novella-Maestre, E., Sanz, R., Gomez, R., Fernandez-Sanchez, M., et al. (2007a). Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism, 92, 2931–2937
   PubMed Web of Science ®Google Scholar
• Alvarez, C., Alonso-Muriel, I., Garcıa, G., Crespo, J., Bellver, J., Simon, C., & Pellicer, A. (2007b). Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study Human Reproduction, 22, 3210–3214.
   PubMed Web of Science ®Google Scholar
• Asch, R.H., Li, H.P., Balmaceda, J.P., Weckstein, L.N., & Stone, S.C. (1991). Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Human Reproduction, 6, 1395–1399.
   PubMed Web of Science ®Google Scholar
• Asch, R.H., Ivery, G., Goldsman, M., Frederick, J.L., Stone, S.C., & Balmaceda, J.P. (1993). The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Human Reproduction, 8, 1015–1020.
   PubMed Web of Science ®Google Scholar
• Babayof, R., Margalioth, E.J., Huleihel, M., Amash, A., Zylber- Haran, E., Gal, M., et al. (2006). Serum Inhibin A, VEGF and TNFa levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Human Reproduction, 21, 1260–1265.
   PubMed Web of Science ®Google Scholar
• Bayram, N., van Wely, M., & van der Veen, F. (2001). Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. The Cochrane Database of Systematic Reviews, 2, CD002121
   Google Scholar
• Benavida, C.A., Davis, O., Kligman I., Moomjy, M., Liu, H.C., & Rosenwaks, Z. (1997). Withholding gonadotrophin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertility and Sterility, 67, 724–727.
   Google Scholar
• Balasch, J., Fábregues, F., Creus, M., Puerto, B., Peñarrubia, J., & Vanrell, J.A. (2001). Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Human Reproduction, 16, 652–656.
   PubMed Web of Science ®Google Scholar
• Bellver, J., Muñoz, E.A., Ballesteros, A., Soares, S.R., Bosch, E., Simón, C., et al. (2003). Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Human Reproduction, 18, 2283–2288.
   PubMed Web of Science ®Google Scholar
• Blankstein, J., Shalev, J., Saadon, T., Kukia, E.E., Rabinovici, J., Pariente, C., et al. (1987). Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertility and Sterility, 47, 597–602.
   PubMed Web of Science ®Google Scholar
• Carizza, C., Abdelmassih, V., Abdelmassih, S., Ravizzini, P., Salgueiro, L., Salgueiro, P.T., et al. (2008). Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive BioMedicine Online, 17, 751–755
   PubMed Web of Science ®Google Scholar
• Chang, P., Kenley, S., Burns, T., Denton, G., Currie, K., DeVane, G., & O’Dea, L. (2001). Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer. Fertility and Sterility, 76, 67–74.
   PubMed Web of Science ®Google Scholar
• Christin-Maitre, S. & Hugues, J.N. (2003). A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Human Reproduction, 18, 1626–1631.
   PubMed Web of Science ®Google Scholar
• Chun, S., Eisenhauer, K., Minami, S., Billig, H., Perlas, E., & Hsueh, A. (1996). Hormonal regulation of apoptosis in early astral follicles: follicle-stimulating hormone as a major survival factor. Endocrinology, 137, 1447–1456.
   PubMed Web of Science ®Google Scholar
• D’Angelo, A. & Amso, N.N. (2002). Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Human Reproduction, 17, 2787–2794.
   PubMed Web of Science ®Google Scholar
• D’Angelo, A. (2010). Ovarian hyperstimulation syndrome prevention strategies: cryopreservation of all embryos. Seminars in Reproductive Medicine, 28, 513–518.
   PubMed Web of Science ®Google Scholar
• D’Angelo, A., Brown, J., & Amso, N.N. (2011). Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews, 6, Art. No.: CD002811. doi:10.1002/14651858.CD002811.pub3.
   Google Scholar
• Delvigne, A., Demoulin, A., Smitz, J., Donnez, J., Koninckx, P., Dhont, M., et al. (1993). The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Human Reproduction, 8, 1353–1360.
   PubMed Web of Science ®Google Scholar
• Delvigne, A., Vandromme, J., Demeestere, I. & Leroy, F. (1997)Unpredictable cases of complicated ovarian hyperstimulation in IVF. International Journal of Fertility and Women's Medicine, 42, 268–270.
   Google Scholar
• Delvigne, A. & Rozenberg, S. (2001). Preventive attitude of physicians to avoid OHSS in IVF patients. Human Reproduction, 16, 2491–2495.
   PubMed Web of Science ®Google Scholar
• Delvigne, A. & Rozenberg, S. (2002a). Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update, 8, 559–577.
   PubMed Web of Science ®Google Scholar
• Delvigne, A. & Rozenberg, S. (2002b). A systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in in vitro fertilisation patients. Human Reproduction Update, 8, 291–296.
   PubMed Web of Science ®Google Scholar
• de Ziegler, D., Streuli, I., Gayet, V., Frydman, N., Bajouh, O., & Chapron, C. (2012). Retrieving oocytes from small non-stimulated follicles in polycystic ovary syndrome (PCOS): in vitro maturation (IVM) is not indicated in the new GnRH antagonist era. Fertility and Sterility, 98, 290–293.
   PubMed Web of Science ®Google Scholar
• Dhont, M., Van der Straeten, F., & De Sutter, P. (1998). Prevention of severe ovarian hyperstimulation by coasting. Fertility and Sterility, 70, 847–850.
   PubMed Web of Science ®Google Scholar
• Doldi, N., Persico, P., Di Sebastiano, F., Marsiglio, E., & Ferrari, A. (2006)Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology, 22, 235–238.
   PubMed Web of Science ®Google Scholar
• Doronzo, G., Russo, I., Mattiello, L., Anfoss,i G., Bosia, A., & Trovati, M. (2004). Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. European Journal of Clinical Investigation, 34, 664–673.
   PubMed Web of Science ®Google Scholar
• Egbase, P.E., Makhseed, M., Al Sharhan, M., & Grudzinskas, J.G. (1997). Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. Human Reproduction, 12, 2603–2606.
   PubMed Web of Science ®Google Scholar
• Egbase, P.E., Sharhan, M.A., & Grudzinskas, J.G. (1999). Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Human Reproduction, 14, 2922–2923.
   PubMed Web of Science ®Google Scholar
• Endo, T., Honnma, H., Hayashi, T., Chida, M., Yamazaki, K., Kitajima, Y., et al. (2002). Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian Hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Human Reproduction, 17, 2548–2551.
   PubMed Web of Science ®Google Scholar
• Engmann L, DiLuigi, A., Schmidt, D., Nulsen, J., Maier, D., & Benadiva, C. (2008). The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian Hyperstimulation syndrome: a prospective randomised controlled study. Fertility and Sterility, 89, 84–91.
   PubMed Web of Science ®Google Scholar
• Enskog, A., Henriksson, M., Unander, M., Nilsson, L., & Brannstrom, M. (1999). Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility, 71, 808–814.
   PubMed Web of Science ®Google Scholar
• Ferraretti, A.P., Gianaroli, L., Magli, C., Fortini, D., Selman, H.A., & Feliciani, E. (1999). Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Human Reproduction, 14, 1457–1460.
   PubMed Web of Science ®Google Scholar
• García-Velasco, J.A., Isaza, V., Quea, G., & Pellicer, A. (2006). Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertility and Sterility, 85, 547–554.
   PubMed Web of Science ®Google Scholar
• Gokmen, O., Ugur, M., Ekin, M., Keles, G., Turan, C., & Oral, H. (2001). Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 96, 187–192.
   PubMed Web of Science ®Google Scholar
• Graf, M.A., Fischer, R., Naether, O.G., Baukloh, V., Tafel, J., & Nuckel, M. (1997). Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme. Human Reproduction, 12, 2599–2602.
   PubMed Web of Science ®Google Scholar
• Gremeau, A.S., Andreadis, N., Fatum, M., Craig, J., Turner, K., McVeigh, E., & Child, T. (2012). In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles. Fertility and Sterility, 98, 355–360
   PubMed Web of Science ®Google Scholar
• Homburg, R. & Howles, C.M. (1999). Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rational, results, reflections refinements. Human Reproduction Update, 5, 493–499.
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Kol, S., Papanikolaou, E.G. on behalf of ‘The Copenhagen GnRH Agonist Triggering Workshop Group. (2011). GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Human Reproduction Update, 17, 510–524.
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Papanikolaou, E.G., Kyrou, D., Alsbjerg, B., Polyzos, N.P., Devroey, P., & Fatemi, H.M. (2012). The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reproductive BioMedicine Online, 24, 134–141.
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Bredkjaer, H.E., Westergaard, L.G., & Andersen, C.Y., (2010). 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertility and Sterility, 93, 847–854.
   PubMed Web of Science ®Google Scholar
• Iliodromiti, S., Blockeel, C., Tremellen, K.P., Fleming, R., Tournaye, H., Humaidan, P., & Nelson, S.M. (2013). Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Human Reproduction, 28, 2529–2536.
   PubMed Web of Science ®Google Scholar
• Jayaprakasan, K., Chan, Y., Islam, R., Haoula, Z., Hopkisson, J., Coomaraswami, A., & Raine-Fenning, N. (2012). Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertility and Sterility, 98, 657–663.
   PubMed Web of Science ®Google Scholar
• Kamath, M.S., Mangalraj, A.M., Muthukumar, K.M., & George, K. (2008). Gonadotrophin releasing hormone antagonist in IVF/ICSI. Journal of Human Reproductive Sciences, 1, 29–32.
   Google Scholar
• Klemetti, R., Sevon, T., Gissler, M., & Hemminki, E. (2005). Complications of IVF and ovulation induction. Human Reproduction, 20, 3293–3300.
   PubMed Web of Science ®Google Scholar
• König, E., Bussen, S., Sutterlin, M., & Steck, T. (1998). Prophylactic intravenous hydroxyethyl starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. Human Reproduction, 13, 2421–2424.
   PubMed Web of Science ®Google Scholar
• Kwee, J., Elting, M.W., Schats, R., McDonnell, J., & Lambalk, C.B.. (2007). Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Human Reproduction, 15, 5–9.
   Google Scholar
• La Marca, A., Giulini, S., Tirelli, A., Bertucci, E., Marsella, T., Xella, S., & Volpe, A. (2007). Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Human Reproduction, 22, 766–771.
   PubMed Web of Science ®Google Scholar
• Lee, T-H., Chung-Hsien, L., Huang, C-C., Wu, Y-L., Shih, Y-T., Ho, H-N., Yang, Y-S., & Lee, M-S. (2008). Serum anti-m llerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles Human Reproduction, 23, 160–167.
   PubMed Web of Science ®Google Scholar
• van der Linden, M., Buckingham, K., Farquhar, C., Kremer, J.A.M., & Metwally, M. (2011). Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews, Issue 10. Art. No.: CD009154. doi:10.1002/14651858.CD009154.pub2
   Google Scholar
• Marci, R., Senn, A., Dessole, S., Chanson, A., Loumaye, E., Grandi, P., & Germond, M. (2001). A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertility and Sterility, 76, 1131–1135.
   Web of Science ®Google Scholar
• Mathur, R.S., Joels, L.A., & Jenkins, J.M. (1995). Ovarian hyperstimulation syndrome may be more likely if multiple pregnancy occurs following assisted conception. Acta Geneticae Medicae et Gemellologiae, 44, 233–235.
   PubMedGoogle Scholar
• Mathur, R.S., Akande, A.V., Keay, S.D., Hunt, L.P., & Jenkins, J.M. (2000). Distinction between early and late ovarian hyperstimulation syndrome. Fertility and Sterility, 73, 901–907.
   PubMed Web of Science ®Google Scholar
• Mathur, R., Hayman, G., Bansal, A., & Jenkins, J. (2002). Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception. Fertility and Sterility, 78, 1154–1158.
   PubMed Web of Science ®Google Scholar
• Matorras, R., Andrés, M., Mendoza, R., Prieto, B., Pijoan, J.I., & Expósito, A. (2013). Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. European Journal of Obstetrics, Gynecology and Reproductive Biology, 8. pii: S0301-2115(13)00317-5. doi:10.1016/ j.ejogrb.2013.07.010. [Epub ahead of print]
   Google Scholar
• Merviel, P., Najas, S., Campy, H., Floret, S., & Brasseur, F. (2005). Use of GNRH antagonists in reproductive medicine. Minerva Ginecologica, 57, 29–43.
   PubMedGoogle Scholar
• Nardo, L.G., Gelbaya, T.A., Wilkinson, H., Roberts, S.A., Yates, A., Pemberton, P., & Laing, I. (2009). Circulating basal anti-Mullerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertility and Sterility, 92, 1586–1593.
   PubMed Web of Science ®Google Scholar
• Mansour, R., Aboulghar, M., Serour, G., Amin, Y., & Abou-Setta, A.M. (2005). Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Human Reproduction, 20, 3167–3172.
   PubMed Web of Science ®Google Scholar
• Nargund, G., Hutchison, L., Scaramuzzi, R., & Campbell, S. (2007). Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reproductive BioMedicine Online, 14, 682–685.
   PubMed Web of Science ®Google Scholar
• Navot, D., Bergh, P.A., & Laufer, N. (1992). Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility, 58, 249–261.
   PubMed Web of Science ®Google Scholar
• Nelson, S.M., Yates, R.W., Lyall, H., Jamieson, M., Traynor, I., Gaudoin, M., et al. (2009.)Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Human Reproduction, 24, 867–875.
   PubMed Web of Science ®Google Scholar
• Nugent, D., Vandekerckhove, P., Hughes, E., Arno, M., & Lilford, R. (2000). Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome (Review). Cochrane Database of Systematic Reviews, 3, Art. No.: CD000410. doi:10.1002/14651858.CD000410.
   Google Scholar
• Orvieto, R. (2005). Can we eliminate severe ovarian hyperstimulation syndrome? Human Reproduction, 20, 320–322.
   PubMed Web of Science ®Google Scholar
• Papanikolaou, E.G., Pozzobon, C., Kolibianakis, E.M., Camus, M., Tournaye, H., Fatemi, H.M., et al. (2006). Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertility and Sterility, 85, 112–120.
   PubMed Web of Science ®Google Scholar
• Papanikolaou, E.G., Verpoest, W., Fatemi, H., Tarlatzis, B., Devroey, P., & Tournaye, H. (2011). A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertility and Sterility, 95, 1174–1177.
   PubMed Web of Science ®Google Scholar
• Peitsidis, P. & Agrawal, R. (2010). Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review. Reproductive BioMedicine Online, 20, 444–452.
   PubMed Web of Science ®Google Scholar
• Pirard, C., Donnez, J., & Loumaye, E. (2006). GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Human Reproduction, 21, 1894–1900.
   PubMed Web of Science ®Google Scholar
• Pundir, J., Sunkara, S.K., El-Toukhy, T., & Khalaf, Y. (2011). Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reproductive BioMedicine Online, 24, 6–22.
   Google Scholar
• Rimington, M.R., Walker, S.M., & Shaw, R.W. (1997). The use of laparoscopic ovarian electrocautery in preventing cancellation of invitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Human Reproduction, 12, 1443–1447.
   PubMed Web of Science ®Google Scholar
• Schwarzler, P., Abendstein, B.J., Klingler, A., Kreuzer, E., & Rjosk, H.-K. (2003). Prevention of severe ovarian hyperstimulation syndrome (OHSS) in IVF patients by steroidal ovarian suppression–a prospective randomized study. Human Fertility, 6, 125–129.
   Google Scholar
• Seyhan, A., Ata, B., Polat, M., Son, W.Y., Yarali, H., & Dahan, M.H. (2013). Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Human Reproduction, 28, 2522–2528.
   PubMed Web of Science ®Google Scholar
• Shaker, A., Zosmer, A., & Dean, N. (1996). Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertility and Sterility, 65, 992–996.
   PubMed Web of Science ®Google Scholar
• Schroder, A.K., Schopper, B., Al-Hasani, S., Diedrich, K., & Ludwig, M. (2003). Unilateral follicular aspiration and in-vitro maturation before contralateral oocyte retrieval: a method to prevent ovarian hyperstimulation syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 110, 186–189.
   PubMed Web of Science ®Google Scholar
• Tan, B.K. & Mathur, R. (2013). Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS Policy and Practice Committee. Human Fertility, 16, 151–159.
   Web of Science ®Google Scholar
• Tang, T., Glanville, J., Orsi, N., Barth, J.H., & Balen, A.H. (2006). The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction, 21, 1416–1425.
   PubMed Web of Science ®Google Scholar
• Tarlatzis, B.C., Fauser, B.C., Kolibianakis, E.M., Diedrich, K., & Devroey, P.; Brussels GnRH Antagonist Consensus Workshop Group. (2006). GnRH antagonists in ovarian stimulation for IVF. Human Reproduction Update, 12, 333–340.
   PubMed Web of Science ®Google Scholar
• Tortoriello, D.V., McGovern, P.G., Colon, J.M., Skurnick, J.H., Lipetz, K., & Santoro, N. (1998). “Coasting” does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertility and Sterility, 69, 454–460.
   PubMed Web of Science ®Google Scholar
• Tozer, A.J., Al-Shawaf, T., Zosmer, A., Hussain, S., Wilson, C., Lower, A.M., & Grudzinskas, J.G. (2001). Does laparoscopic ovarian diathermy affect the outcome of IVF-embryo transfer in women with polycystic ovarian syndrome? A retrospective comparative study. Human Reproduction, 16, 91–95.
   PubMed Web of Science ®Google Scholar
• Tozer, A., Iles, R., Iammarrone, E., Guillott, C., Al-Shawaf, T., & Grudzinskas, J. (2004). The effects of coasting on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome. Human Reproduction, 19, 522–528.
   PubMed Web of Science ®Google Scholar
• Tso, L.O., Costello, M.F., Andriolo, R.B., & Freitas, V. (2009). Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 2, Art. No.: CD006105. doi:10.1002/14651858.CD006105.pub2.
   Google Scholar
• van Wely, M., Kwan, I., Burt, A.L., Thomas, J., Vail, A., Van der Veen, F., & Al-Inany, H.G. (2011). Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews, 2, Art. No.: CD005354. doi:10.1002/14651858.CD005354.pub2.
   Google Scholar
• Venetis, C.A., Kolibianakis, E.M., Toulis, K.A., Goulis, D.G., Papadimas, I., & Tarlatzis, B.C. (2011). Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertility and Sterility, 95, 188–196.
   PubMed Web of Science ®Google Scholar
• Yates, A.P., Rustamov, O., Roberts, S.A., Lim, H.Y.N., Pemberton, P.W., Smith, A., & Nardo, L.G. (2011). Anti-Müllerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Human Reproduction, 26, 2353–2362.
   PubMed Web of Science ®Google Scholar
• Youssef, M.A., van Wely, M., Hassan, M.A., Al-Inany, H.G., Mochtar, M., Khattab, S., & van der Veen, F. (2010). Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Human Reproduction Update, 16, 459–466.
   PubMed Web of Science ®Google Scholar
• Youssef, M.A., Van der Veen, F., Al-Inany, H.G., Griesinger, G., Mochtar, M.H., Aboulfoutouh, I., et al. (2011a). Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database of Systematic Reviews, 1, Art. No.: CD008046. doi:10.1002/14651858.CD008046.pub3.
   Google Scholar
• Youssef, M.A., Al-Inany, H.G., Aboulghar, M., Mansour, R., & Abou-Setta, A.M. (2011b). Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database of Systematic Reviews, 4, Art. No.: CD003719. doi:10.1002/14651858.CD003719.pub3.
   Google Scholar
• Youssef, M.A., Al-Inany, H.G., Evers, J.L.H., & Aboulghar, M. (2011c). Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD001302. doi:10.1002/14651858.CD001302.pub2.
   Google Scholar
• Yovich, J., Stanger, J., & Hinchliffe, P. (2012). Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reproductive Biomedicine Online, 24, 281–292.
   PubMedGoogle Scholar
• Zhu, W.J., Li, X.M., Chen, X.M., & Zhang, L. (2005). Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization. European Journal of Obstetrics, Gynecology and Reproductive Biology, 122, 79–84.
   PubMed Web of Science ®Google Scholar